Gao SS, Zhang GX, Zhang WT. MicroRNAs as prognostic biomarkers for survival outcome in osteosarcoma: A meta-analysis. World J Meta-Anal 2021; 9(6): 568-584 [DOI: 10.13105/wjma.v9.i6.568]
Corresponding Author of This Article
Wen-Ting Zhang, PhD, Doctor, International Doctoral School, University of Seville, Calle San Fernando, 4, Seville 41004, Spain. 724521882@qq.com
Research Domain of This Article
Orthopedics
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Dec 28, 2021; 9(6): 568-584 Published online Dec 28, 2021. doi: 10.13105/wjma.v9.i6.568
MicroRNAs as prognostic biomarkers for survival outcome in osteosarcoma: A meta-analysis
Shuai-Shuai Gao, Guo-Xun Zhang, Wen-Ting Zhang
Shuai-Shuai Gao, Guo-Xun Zhang, Wen-Ting Zhang, International Doctoral School, University of Seville, Seville 41004, Spain
Shuai-Shuai Gao, Department of Traumatology and Orthopedic Surgery, Xi'an Daxing Hospital, Xi'an 710016, Shaanxi Province, China
Author contributions: Gao SS drafting the article; Gao SS and Zhang GX searching of literature, acquisition of data; Gao SS and Zhang WT analysis and interpretation of data; Gao SS, Zhang GX and Zhang WT did final approval; Zhang GX revising the article; Zhang WT conception and design of the study, critical revision.
Conflict-of-interest statement: The authors deny any conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Ting Zhang, PhD, Doctor, International Doctoral School, University of Seville, Calle San Fernando, 4, Seville 41004, Spain. 724521882@qq.com
Received: August 7, 2021 Peer-review started: August 7, 2021 First decision: October 2, 2021 Revised: October 8, 2021 Accepted: December 24, 2021 Article in press: December 24, 2021 Published online: December 28, 2021
ARTICLE HIGHLIGHTS
Research background
Osteosarcoma is one of the most common primary malignant bone tumors in children, with rapid progress and poor prognosis. microRNA (miRNA) has been proposed as a valuable biomarker for the prognosis of osteosarcoma, but the results are not consistent.
Research motivation
We wished to gain a detailed insight into the effect of circulating miRNA on the prognosis of patients with osteosarcoma.
Research objectives
The aim of this meta-analysis was to study the prognostic value of miRNA expression in patients with osteosarcoma.
Research methods
A literature search was conducted to identify studies published through July 1, 2021. Random-effects meta-analyses were conducted for combinations of the outcomes of overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival in osteosarcoma patients. Subgroup analyses were conducted to identify sources of heterogeneity. Publication bias was assessed by Egger’s bias indicator test.
Research results
A total of 60 studies were included for this meta-analysis. The pooled HR for OS, DFS, PFS were 2.92 (95%CI: 2.43-3.41, P = 0.000), 3.70 (95%CI: 2.80-4.61, P = 0.000), and 3.57 (95%CI: 1.60-5.54, P = 0.000), respectively. The high expression levels of miR-21 were associated with poor OS in osteosarcoma (HR = 2.86, 95%CI: 1.20-4.53, P = 0.001).
Research conclusions
Circulating miRNA could be used as a potential prognostic biomarker for osteosarcoma.
Research perspectives
Evidence from later studies could consolidate these conclusions. A large number of samples prospective studies are needed in the future to enhance the persuasiveness of our conclusion.
